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Abstract
Background: Recent studies indicate an increased incidence of pertussis disease in recent years. The aim of
this study was to evaluate the efficacy of the acellular vaccine for children (as a replacement of current whole
cell vaccine in the Expanded Program on Immunization) and for high-risk adults in Iran through updating cur-
rent best available evidence.
Methods: We performed a systematic literature review in relevant databases we focused on previously published
systematic reviews to select those that address our questions. The AMSTAR (assessing the methodological quality of
systematic reviews) tool was used for screening available reviews. Then search in databases was done until Feb 2014
to update the evidence. We pooled results using meta-analysis methods by Stata statistical package.
Results: Eleven systematic review articles were included in the initial evaluation. In the end, two systematic
reviews on acellular vaccine booster doses and the acellular vaccine in children were selected as the baseline
evidence. In the update phase, new clinical trials were screened, and the results were updated. Overall pooled
estimate of relative efficacy of acellular to whole cell was 0.68 (95% CI, 0.55–0.81) for children immunization
Pooled estimates for the efficacy of acellular versus placebo were 0.70 (95% CI, 0.60–0.80). Overall pooled
estimate of efficacy of booster dose of acellular was 0.87(95% CI, 0.85–0.88) compared to placebo. In addition
pooled estimate of acellular vaccine efficacy based on response to antigen was 0.78(95% CI, 0.64–0.93) in high-
risk group.
Conclusion: The results show higher performance and safety of the acellular vaccine in the prevention of pertus-
sis in children versus the whole cell vaccine. Moreover, the efficacy of the acellular vaccine in high-risk adult
groups is acceptable. This study provides evidence in favor of the introduction of an acellular vaccine to the na-
tional program of immunization. Studies on cost effectiveness and aspects of policy analysis are recommended.
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Introduction
Whooping cough is an acute bacterial
respiratory disease, caused by Bordetella
pertussis. It can be transmitted through na-
sal and pharyngeal discharges. This disease
has a high degree of virulence. Also the
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bacteria has a high attack rate (80-100%)
(1). Immunization against whooping cough
is widely coverage by whole-cell vaccine
which was developed in the 1940s (2).
Most of the whole-cell vaccines are mixed
with Diphtheria and Tetanus toxoids, unde-
sired chemicals like endotoxins which are
side products of whole cell vaccines cause
side effects for this kind of vaccines. Due
to growing concerns about the neurologic
disorders related to whole-cell vaccines,
Acellular vaccines were produced and test-
ed in 1970 and were used in 1980 in Japan
(3,4). Increasing in the incidence of pertus-
sis in adolescents suggesting that the im-
munity by the acellular vaccine may be
more efficient than whole-cell vaccine (5),
although according to the technical adviso-
ry group on vaccine-preventable diseases
(TAG), countries that are using whole-cell
vaccine should not switch to an acellular
vaccine. Similarly, countries currently us-
ing acellular should not switch back to the
use of whole-cell until more evidence is
available to support changes in vaccination
strategies for pertussis (5). In Iran, in spite
of vaccination program covering more than
90% of the population, reports show an in-
creasing trend of incidence rate in some
years which may be due to lack of control
in adults (6). This study was designed and
performed in order to reach the best estima-
tion of vaccine efficacy and also as an in-
troduction to cost-effectiveness analysis of
acellular vaccination in Iran for providing
strong evidence for health policy makers.
Methods
We tried to systematically answer three
questions in this study:
What is the relative efficacy of acellular
pertussis vaccine compared to the whole
cell vaccine in children of fewer than five
years old?
What is the efficacy of an additional
booster dose of acellular pertussis vaccine
compared to placebo in fully immunized
children with whole cell pertussis?
What is the efficacy of a booster dose of
acellular pertussis vaccine compared to
placebo in high-risk adults (healthcare staff
and pregnant women)?
First, we performed a systematic review
on review studies of acellular vaccine effi-
cacy in: 1. children, 2. Health care worker,
3. pregnant women and 4. Booster dose of
acellular pertussis vaccine. We selected a
core systematic review for each of the
above-mentioned groups, considering
quality factors of AMSTAR (assessing the
methodological quality of systematic re-
views) and publication time of the review.
Then we performed a systematic review of
clinical trials of the acellular vaccine in or-
der to update core reviews.
Search strategy
In order to retrieve related studies we
used Pertussis Vaccine/ Whooping Cough/
whoop/ Bordetella pertussis/ Vaccines,
Acellular/ Meta-analysis/ review/ systemat-
ic review
Keywords in relevant evidence base med-
icine database via Ovid S.P.
To arrange the search strategy, since there
was a related systematic review in
Cochrane (8) we used a searching method
in this review as a guidance to develop a
final search strategy. For the secondary
studies in MEDLINE, we used CRD which
is a very precise strategy (9). Also, we used
Cochrane recommended methods of sys-
tematic searching (10). Also, we used
PUBMED recommended strategy for sys-
tematic review and for the secondary stud-
ies in another database. We used Lee et al.
method (11-13). Search in databases was
done in August 2012 by a clinical librarian
(FSH) and we did not limit our search to a
certain language or time period.
Search resources
We conducted a search strategy in Med-
line via Ovid, EMBASE via Ovid, EBM
Reviews via Ovid, CINAHL and PUBMED
via EBSCOhost. Other references such as
CEA Registry, Pediatric Economic Data-
base Evaluation, EURONHEEDs and
Google Scholar were used for covering
gray literature and to increase the sensitivi-
D
ow
nl
oa
de
d 
fro
m
 m
jiri
.iu
ms
.ac
.ir 
at 
20
:17
 IR
ST
 on
 Tu
es
da
y D
ec
em
be
r 1
7th
 20
19
R. Mansour-Ghanaei, et al.
3Med J Islam Repub Iran 2016 (29 November). Vol. 30:451. http://mjiri.iums.ac.ir
ty of the search. We did a manual reference
checking and citation tracking of related
papers. In every step of searching, we were
considered PRISMA statement (14). First,
as our objective was finding relevant sys-
tematic reviews and updating them, we up-
dated our search in February 2013, in case
to recheck are the references of the system-
atic reviews which have been chosen as
core review. For updating the research we
used Cochrane updating protocol. We used
a combination of the following words in the
updating step of our research:
Pertussis Vaccine/ Whooping Cough/
Bordetella pertussis/ Vaccines, Acellular/
(“Quantitative Studies”/ (“Placebos”) ran-
dom* or AB random* (single* blind* or
double* blind* or triple* blind* or treble*
blind* or single* mask* or double* mask*
or triple* mask* or treble* mask*) or AB
(single* blind* or double*)
The following references have been used
in the updating step: Biological Abstracts,
EBM Reviews - Cochrane Central Register
of Controlled Trials <January 2014>, CI-
NAHL with Full Text, EMBASE<1974 to
2014 February 06>, Ovid MEDLINE(R)
In-Process & Other Non-Indexed Citations
and Ovid MEDLINE(R) <1946 to Pre-
sent>.
Inclusion criteria
In the first phase of screening, all of the
systematic reviews with or without meta-
analysis were included. In the updating
phase all the RCTs (randomized clinical
trial), quasi-RCTs and immunogenicity
studies were included. The study popula-
tion included children less than 6 years old
from the general population, adolescent and
high-risk groups including pregnant women
and health care workers. The interventions
were evaluated with four different analyti-
cal strategies. The first strategy was as-
sessing acellular vaccine for children com-
pared to placebo, the second strategy was
assessing acellular vaccine for children
compared to whole cell vaccine, the third
one was assessing the booster dose of acel-
lular vaccine (booster vaccination after 10
years) compared to no-booster and the
fourth one was acellular vaccine to the
high-risk group compared to placebo or un-
related vaccines.
Exclusion criteria
Laboratory studies conducted on animals
were excluded. Also, studies using non-
standardized methods were excluded from
this study.
Study selection
Full-texts of the relevant studies were
critically appraised for eligibility criteria by
two researchers independently (MY and
SSH). Flow diagram of articles included in
the systematic review is shown in (Fig. 1).
Outcome Assessment
The primary outcome was the clinical ef-
ficacy of the vaccine to prevent disease
during the follow-up period, and the sec-
ondary outcome was the immunity in that
period. Disease had been defined in two
different ways in clinical trials. Based on
the first definition whooping cough is a
disease with 21 days long lasting continues
coughs by Bordetella pertussis which has
been proved with positive cell culture, posi-
tive serological tests or having contact with
a known case of disease which had been
proved with two positive cultures (WHO
1991). In the other definition, the disease is
having 7 days of continues coughs with a
positive cell culture or serologic test (8).
Data extraction
Data extraction was carried out by two re-
searchers (MY, SSH). Year of publication,
year of study, location of study, study de-
sign, number of patients in the study, num-
ber of patients in each group, age range and
type of vaccine synchronizing with other
vaccines administered, duration of follow-
up, number of doses and study phase were
extracted., Outcome indicators such as rela-
tive risk, odds ratio, and response rates
(percent) to the antigen for high-risk group
were extracted from the studies as well.
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Quality assessment
The systematic review studies were as-
sessed with AMSTAR (A program that as-
sesses the quality of the articles in 11 dif-
ferent areas.), and the clinical trials were
assessed with CASP (Critical Appraisal
Skills Programme (CASP) tool) (15,16).
Data Synthesis
The statistical analyses were done via
STATA version 11. Indicators for assessing
the clinical trials were risk ratio (RR) or
odds ratio (OR). For the high-risk group,
we did not find enough studies to assess
clinical outcomes through RR or OR, so,
we assessed the vaccine immunogenicity
and analysis was performed on the response
rate to the antigen. For calculating the vac-
cine efficacy, we used RR-1 formula (17).
Moreover, publication biases of the studies
were assessed via Funnel-plot with regres-
sion asymmetry test (Egger’s test). Hetero-
geneity of the studies was assessed with
Cochrane Q-test. All pooled estimates were
calculated by random effect model (except
the cases of no significant heterogeneity).
Subgroups were determined based on four
strategies for the vaccination program.
Results
Study selection
The electronic searching identified 1026
abstract from databases. After the initial
screening of title/abstract by two research-
ers (MY, SSH), 853 abstracts were exclud-
ed from the analysis and a total of 173 stud-
ies were selected for further investigation
and extracting data from full texts. Finally,
11 review studies (8,18-26) in the initial
evaluation were criticized with the AM-
STAR tool by three researchers (MY, SSH,
MML) (Table 1). Finally, we selected ---
Table 1. Specifications of systematic review of acellular vaccine efficacy
ReferenceStudy TypeCountryYearFirst AuthorNo
18Systematic ReviewAustralia2000Tinnion ON.1
8Systematic ReviewBrazil2012Zhang2
19Systematic ReviewUK2012Rodriguez4
20Systematic ReviewUSA2011Johns T.L5
21Systematic ReviewNew Zealand2009Plosker G.L.6
22Systematic ReviewBrazil2006de Carvalho7
23Systematic ReviewItaly2003Jefferson T8
24Systematic ReviewUSA1994Wintermeyer S.M9
25Systematic review and Meta-analysisSpain1996Gil A.10
26Systematic ReviewAustralia2011Tinnion O11
Table 2. Specifications of clinical trials that estimated acellular vaccine efficacy
No First Author Year Intervention Population Age Efficacy (95% CI) Reference
1. Gustafsson 1996 DTaP vs placebo 2566 Children <6  27
2. Trollfors 1995 DTaP vs placebo 96 Children <6  28
3. Greco 1996 DTaP vs placebo 37 Children <6  29
4. Ahgspv 1997 DTaP vs placebo 1428 Children <6  30
5. PVSG 1998 DTaP vs placebo 4273 Children <6  31
6. Joel I. Ward 2005 DTaP vs placebo 1391 Children <6  32
7. Salmaso 2012 DTaP vs placebo 126 Children <6  33
8. De Serres G 2001 DTaP –Booster 25 Adult  34
9. González Morán F 2002 DTaP -Booster 130 Adult  35
10. Iskedjian 2005 DTaP -Booster 90929 Adult  36
11. Stevenson 2002 DTaP -Booster 14332 Adult  37
12. Edmunds 2002 DTaP -Booster 1165 Adult  38
13. Caro 2005 DTaP -Booster 68000 Adult  39
14. Lee 2004 DTaP -Booster 69 Adult  40
15. Gustafsson 1996 DTaP vs DTwp 2587 Children <6  27
16. Greco 1996 DtaP vs DTwp 36 Children <6  29
17. Simondon 1997 DtaP vs DTwp 1772 Children <6  41
18. Ahgspv 1997 DtaP vs DTwp 1419 Children <6  30
19. Patrick Olin 1997 DtaP vs DTwp 20728 Children <6  42
20. Patrick Olin 1997 DtaP vs DTwp 20747 Children <6  42
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systematic reviews to be used as a base
(core systematic review) for answering
each of the four questions of this study: the
Zhang et al. (9) review article (2012) for
acellular vaccine in children, the Rodriguez
et al. (19) review article for booster vaccine
were obtained as core reviews for analyzing
data about vaccine safety and efficacy. We
updated these reviews through our protocol
for finding new clinical trials through a sys-
tematic review. We classified new trials in
the four subgroups; then Meta-analyses
were performed to create pooled estimates
for vaccine efficacy. In the updating phase,
clinical trial studies were screened, and a
total of 2 clinical studies out of 20 studies
were added to the core systematic review
(32,33). Finally, we obtained 15 studies
(27-42) from core systematic reviews and
clinical trials extracted from updating
phase, among them we included 7 interven-
tions for the efficacy of acellular vaccine
versus placebo, 6 interventions for the effi-
cacy of acellular vaccine versus whole cell,
7 interventions for the efficacy of acellular
vaccine booster dose (Table 2). In addition,
two review articles were analyzed for as-
sessing the vaccine efficacy in the high-risk
group as an immunological response in
pregnant women and health workers
(42,43).
Meta-analysis results
Six studies on 51,548 children less than 6
years old had assessed the relative efficacy
of acellular vaccine compared to the whole
Fig.1. Flow of studies through the review process
Records after duplicates removed
(n = 173)
Review assessed for quality
(n =11)
Reviews included in the
quantitative synthesis
(n = 2) with 13 clinical trials
Clinical trials included in in
meta-analysis
(n = 15)
Records identified through relevant database
(n = 1026)
Excluded (n=162)
Not-relevant in title / abstract
(n=113)
No outcome were reported
(n= 49)
Updating Phase:
Clinical trials identified through
relevant database (n=20)
Clinical Trials added to core
review (n=2)
Duplicate excluded (n=853)
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cell. There was considerable heterogeneity
between results of the studies (Q=54.4,
p<0.001, I2=91%), and pooled estimate of
relative efficacy of acellular vaccine to the
whole cell in random model was 0.68 (95%
CI: 0.55-0.81) (Table 4 and Fig. 2) Seven
studies on 9,971 children less than 6 years
old had assessed relative efficacy of acellu-
lar vaccine compared to placebo. There was
considerable heterogeneity between results
of the studies (Q=43.6, p<0.001, I2=86%),
and pooled estimate of relative efficacy of
the acellular vaccine to placebo in the ran-
dom model was 0.70 (95% CI: 0.60-0.80)
(Table 4 and Fig. 3).
Seven studies on 176,650 adults had as-
sessed the efficacy of acellular vaccine
booster dose. There was a considerable het-
erogeneity between results of the studies
(Q=383.7, p<0.001, I2=98%), and pooled
estimate of efficacy of acellular vaccine
booster dose in the random model was 0.87
(95% CI: 0.85-0.88) (Table 4 and Fig. 4).
Two studies on 69,285 in adults had as-
sessed the efficacy of the acellular vaccine
in high-risk population. There was consid-
erable heterogeneity between results of the
studies (Q=51.3, p<0.001, I2=92%), Pooled
Fig. 2. Funnel-plot for overall pooled estimate of relative efficacy of acellular vaccine versus whole cell
Fig. 3. Funnel-plot for overall pooled estimate of relative efficacy of acellular vaccine versus placebo
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estimate of antigen response rate to the
acellular vaccine in high-risk group in ran-
dom model was 0.78 (95%CI: 0.64-0.93)
Publication bias on assessment of the ef-
ficacy of acellular vaccine versus the whole
cell vaccine, as well as the efficacy of acel-
lular vaccine versus placebo with Egger &
Begg test were examined, which indicates
no bias. Summary of efficacy results is
shown in Table 3.
Safety result
Evaluating the complications of the acel-
lular and the whole cell vaccine with the
data exerted from the systematic review
articles indicate that the pooled estimate of
relative risk of all complications after vac-
cination with acellular vaccine against
whole cell vaccine is 1.02(95%CI: 0.99-
1.05). Moreover, according to studies, the
incidence of seizure complication following
whole-cell vaccine was 1 in 1,750 cases.
Fig. 4. Funnel-plot graph for overall pooled estimate of relative efficiency of acellular vaccine booster doses
Table 3. Specifications of studies estimated response to antigen in high-risk group
SEResponse rateAntibodyPopulationYearFirst AuthorNo
7.420.833PT-IgG83342011Gall SA,1.
6.220.1PT-IgA83342011Gall SA,2.
6.220.9FHA-IgG83342011Gall SA,3.
9.230.633FHA -IgA83342011Gall SA,4.
7.420.833PRN-IgG83342011Gall SA,5.
7.880.8PRN- IgA83342011Gall SA,6.
5.890.872PT-IgG29962011Gall SA,7.
8.320.436PT-IgA29962011Gall SA,8.
6.170.9FHA-IgG29962011Gall SA,9.
7.190.769FHA -IgA29962011Gall SA,10.
6.630.821PRN- IgA29962011Gall SA,11.
2.301PRN-IgG29962011Gall SA,12.
7.420.97PT-IgG2612008Littmanna13.
7.880.634PT-IgA2612008Littmanna14.
5.890.992FHA-IgG2612008Littmanna15.
8.320.963FHA-IgA2612008Littmanna16.
6.170.972PRN-IgG2612008Littmanna17.
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Discussion
Results of the current review in order to
estimate the pooled estimate of efficacy of
acellular whooping cough vaccine when
used with multiple strategies as vaccination
of children and booster doses for adults and
high-risk groups (pregnant women and
health care worker), illustrates that applica-
tion of acellular vaccine in children reduces
the incidence of disease by 60-80%. The
estimated efficacy compared with whole-
cell vaccine is 55-81%. Efficacy of acellu-
lar vaccine in booster doses in adults avert-
ed disease in this age group by 85-88%. In
high-risk groups after investigating the
immune response, the cases averted has
been estimated 64-93% in a random model.
A review study conducted with Cochrane
by Zhang et al. (8) in 2012 in order to de-
termine the efficacy and safety of acellular
vaccine in children less than 6 years old. In
that review study, the efficacy of the vac-
cine was shown in 6 clinical trials designed
for the defined consequences.  Efficacy of
vaccines with more than 3 particles to pre-
vent typical whooping cough disease is 84-
85% and efficacy to prevent mild whooping
cough disease is 71-78%. In the current
study according to the updates performed,
pooled estimate of efficacy of the acellular
vaccine was 71-77%.
Vaccine safety is one of the first issues in
this field that is studied in Zhang’s review
article, and because of that, we didn’t dis-
cuss it in the present study. In the men-
tioned review study, major and minor side
effects were studied in 52 clinical trials in
136541 children and cumulative efficacy of
the acellular and whole-cell vaccines were
compared in various doses. Study indicated
that risk ratio (RR) of major side effects as
death, encephalopathy, seizures and hypo-
tonic posture in the first dose of acellular
vaccine compared to the whole cell vaccine
were 0.97 , 0.00 , 0.47 , 0.26 respectively
and risk ratio in minor side effects like ano-
rexia, prolong crying and high fever were
estimated 0.43, 0.17, 0.15 respectively.
These numbers increased slightly in the
next doses (8). Assessing acellular vaccine
was considered because of fewer side ef-
fects than whole cell vaccine, especially
neurologic side effects. On the other hand,
the limitations of using whole cell vaccine
in adults as well as not making a lifetime
security by using whole cell vaccine in
children causing poor control of the dis-
ease, incidence of disease in adults and
transmission of it to other groups in a socie-
ty are known. There are studies in this field
, for example, Pertussis incidence rates in
two decades in the United States has in-
creased steadily while during the process
that vaccination rates among children were
high. During the years 1997 to 2000, most
of the cases, according to the Center for
Disease Control and Prevention (CDC)
were infants (55.5%) and patients of 10 to
19 years old (29%). But in 2005, 60% of
the reported cases were among adolescents
of 10 to 18 years old (46) from the reasons
of increasing in this disease reports, up-
grade of diagnostic procedures and increase
awareness about the disease was noted.
However, many studies have shown that
immunity after vaccination decreases over
time and protection may only be 10 to 15
years which this can increase the number of
susceptible individuals among adolescents
and adults. The study conducted by Nikbin
et al. (6) in the ministry of health in Iran
indicated that the number of susceptible
and diagnosed whooping cough patients is
recently increasing. The reasons for this
Table 4. Results of subgroup Meta analyses
Subgroup No. of
Studies
Heterogeneity Pooled Estimate
X2 p I2 Random (95%CI) Fixed (95%CI)
DTap vs DTwP 6 54.4 <0.001 91 0.68 (0.55-0.81) 0.80 (0.77-0.84)
DTaP vs Placebo 7 43.6 <0.001 86 0.70 (0.60-0.80) 0.73 (0.70-0.77)
DTaP booster dose vs. no booster 6 373.7 <0.001 98 0.87 (0.85-0.88) 0.853 (0.851-0.854)
DTap in high risk groups vs. no
vaccine
2 51.3 <0.001 92 0.78 (0.64-0.93) 0.766 (0.764, 0.768)
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increase in the article were the same as we
mentioned here. It has been described that
most cases have been confirmed among
children due to the less attention of the dis-
ease among adults. In a review study by
Rodriguez (19) in 2012, the clinical effica-
cy of direct and indirect (herd immunity) of
vaccine booster dose with different strate-
gies was evaluated and calculated. Twenty
one observational studies entered into the
analysis and were estimated using mathe-
matical modeling. Direct result of the vac-
cination (reduction of the incidence was 37-
64% in adolescents and 39-50% in adults
vaccinated) was estimated, and indirect ef-
fects or community immunity (18-22% re-
duction in the incidence of disease in ado-
lescents and 33% in adults) was calculated.
Highlights from a study conducted by Ro-
driguez, is computing the community im-
munity, which is an explanation for the ep-
idemiologic process change and the use of
booster doses (19).
Control of disease in high-risk groups
such as pregnant women to maintain safety
in infants and employees of the health sys-
tem as a factor for infection and transmis-
sion also had been considered. This point
makes us remember the importance of
booster dose in adults. In most cases, the
disease incidence in adults is directly relat-
ed to epidemiology in health care workers
(21,22) .In a study conducted by Wright et
al. in 1992 among emergency room staff, a
serological survey showed that despite high
immunization coverage in children, anti-
body levels were low in the majority of
employees. This caused this group to be at
high risk for infection and subsequent
transmission of pertussis to susceptible in-
dividuals. The incidence of Bordetella per-
tussis among health professionals was 3.1%
at 95% confidence level (CI) (5.3%-0.00)
among 106 physicians, 6.3% at 95% CI
(6.9%-0.00) among the physicians and
nurses of emergency department (19).
On the positive side, this review performs
an integrate search of the information and
estimates the pooled efficacy rates and
compiles different kinds of strategies. To
conclude, to demonstrate the efficacy and
safety of acellular vaccines, considering the
widespread use of vaccines in children with
higher safety and booster doses among
adults especially high-risk groups to pro-
mote safety in this group to eliminate or
reduce the transmission cycle is recom-
mended. In addition, performing cost-
effectiveness analysis for implementing
acellular vaccine in national immunization
program in Iran seems necessary.
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